Orgonex partners with HUB Organoids to scale dynamic 3D organoid culture

We’re thrilled to highlight a new milestone from our Venture Challenge Summer 2021 alumnus: Orgonex B.V. has announced that HUB Organoids, now part of Merck Group, is among the first to adopt its groundbreaking RPMotion bioreactor platform.

HUB Organoids is globally recognized for its patient-derived organoid technology, providing powerful in vitro models that accelerate drug discovery and development. With the integration of Orgonex’s bioreactor system, the team takes a major step forward in enabling dynamic 3D organoid culture, offering drug developers enhanced functionality, precision, and translational relevance.

“We’re excited to support HUB Organoids in their innovative work with our organoid-specific bioreactor,” said the Orgonex team, including Bart Spee, Kerstin Schneeberger - Verjaal, and Marleen van Nuenen, PhD, MSc.

This collaboration underlines Orgonex’s commitment to empowering translational research and expanding a thriving user community at the forefront of biomedical innovation.

Congratulations to the entire team on this important step forward — we look forward to seeing where the RPMotion platform will go next!

Source: LinkedIn